Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ARCT vs DMAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Captures Overall Composite Edge (46.3 HOLD vs 57.7 HOLD), While ARCT Leads 3–2 on Growth & Valuation Pillars

DMAC Overall Winner 6-Pillar Tally: ARCT 3 – 2 DMAC (1 Tie) Matrix Metrics: ARCT 5 – 5 DMAC

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Arcturus Therapeutics Holdings Inc. (ARCT) on higher Unified Composite conviction (46.3/100 HOLD vs. 57.7/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while ARCT wins 3–2 across the 6-pillar growth and valuation breakdown. ARCT trades at $8.43 (2.5x Forward P/E, -311.2% operating margin) versus DMAC at $8.39 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ARCT currently prints a higher short-term Unified Composite Score (57.7/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -311.2% operating margin) and revenue trajectory (+0.0% vs. +6.7% YoY).
  • Technical & Structure Timing Caution: ARCT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.1); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARCT vs DMAC
ARCT NASDAQ
Arcturus Therapeutics Holdings Inc. Common Stock
Pharmaceutical Preparations
$8.43
+0.84% 1D
Market Cap $241.0M
TTM Revenue $31M
Forward P/E 2.5x
Beta / 30D Vol 2.01β · 127% Vol
Unified Composite Score
57.7 / 100 HOLD
Tech 60.0 Fund 62.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 39
RSI-14: 39.1 · SMA20: $10.11 · SMA50: $12.28
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.39
-4.55% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.72β · 97% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.7 · SMA20: $9.24 · SMA50: $8.24

6-Pillar Scorecard Institutional Category Breakdown (ARCT 3 – 2 DMAC)

Columns: Metric · ARCT · DMAC
1. Valuation Multiples ARCT
Forward P/E 2.5x N/M
Trailing P/E 2.5x N/M
PEG Ratio N/M N/M
EV / Revenue 2.6x N/M
2. Growth & Scale ARCT
Revenue Growth (YoY) +6.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $31M N/A
Market Cap $241.0M $503.1M
3. Profitability & Quality DMAC
Gross Margin N/A N/A
Operating Margin -311.2% 0.0%
Net Profit Margin -285.9% 0.0%
Return on Equity (ROE) -44.4% -114.6%
4. Balance Sheet & Cash Flow ARCT
Cash Generation (TTM) -$62M -$32M
Cash Flow Margin N/A N/A
Net Cash / Leverage $163M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DMAC
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 96.3% (7th %ile) 106.3% (14th %ile)
Put/Call OI Skew 0.07x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARCT (5) vs DMAC (5)
Institutional Metric ARCT DMAC Criterion Row Edge
Market Capitalization
Scale
$241.0M $503.1M Larger Scale DMAC
Trailing P/E Ratio
Valuation
2.5x N/M Lower Multiple ARCT
Forward P/E Ratio
Valuation
2.5x N/M Lower Multiple ARCT
Revenue Growth (YoY)
Growth
+6.7% +0.0% Higher Growth ARCT
Operating Margin (TTM)
Profitability
-311.2% 0.0% Higher Margin DMAC
Net Profit Margin
Profitability
-285.9% 0.0% Higher Margin DMAC
Return on Equity (ROE)
Capital Efficiency
-44.4% -114.6% Higher ROE ARCT
52-Week Range Position
Momentum
24% ($6–$18) 55% ($5–$11) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
2.01β · 127% Vol 1.72β · 97% Vol Lower Realized Risk DMAC
Unified Institutional Score
Composite Signal
57.7 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite ARCT
Trailing 12M Revenue (USD)
Operating Scale
$31M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$62M ($163M Net Cash) -$32M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +29.3 pp
ARCT: -18.47% · DMAC: +10.83%
3M Horizon DMAC +24.25 pp
ARCT: +2.68% · DMAC: +26.93%
6M Horizon DMAC +27.8 pp
ARCT: +19.91% · DMAC: +47.71%
1Y Horizon DMAC +46.31 pp
ARCT: +8.49% · DMAC: +54.8%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ARCT Revenue DMAC Revenue ARCT Op. Margin DMAC Op. Margin Margin Leader
FY2018 $20M $0M -138.5% -1352.2% ARCT
FY2019 $20M N/A -122.7% N/A ARCT
FY2020 $10M N/A -749.8% N/A ARCT
FY2021 $10M N/A -1641.3% N/A ARCT
FY2022 $210M N/A 5.9% N/A ARCT
FY2023 $170M N/A -46.9% N/A ARCT
FY2024 $150M N/A -62.8% N/A ARCT
FY2025 $80M N/A -93.0% N/A ARCT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARCT BREAKDOWN
42d in phase · OBV DISTRIBUTION
Current IV 96.3%
IV Percentile 7th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARCT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $241.0M market capitalization and -311.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ARCT vs DMAC Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Arcturus Therapeutics Holdings Inc. (ARCT) on higher Unified Composite conviction (46.3/100 HOLD vs. 57.7/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while ARCT wins 3–2 across the 6-pillar growth and valuation breakdown. ARCT trades at $8.43 (2.5x Forward P/E, -311.2% operating margin) versus DMAC at $8.39 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ARCT currently prints a higher short-term Unified Composite Score (57.7/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -311.2% operating margin) and revenue trajectory (+0.0% vs. +6.7% YoY). Technical & Structure Timing Caution: ARCT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.1); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ARCT leads the Growth & Scale pillar: ARCT posts +6.7% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (N/A gross margin, -311.2% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ARCT cumulative revenue shifted +300.0% while DMAC shifted N/A. In operating R&D and SG&A reinvestment, ARCT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.

ARCT screens cheaper on headline valuation multiples. ARCT trades at 2.5x Forward P/E, 2.5x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (unreported FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARCT (-44.4% ROE) versus DMAC (-114.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ARCT carries 96.3% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 127% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.72β · 97% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.